Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing immunotherapy drugs targeting the adenosine pathway for cancer treatment. The company's lead candidate, mupadolimab (CPI-006), is in Phase 2/3 trials for peripheral T-cell lymphoma and other hematologic malignancies, with potential regulatory milestones in 2026-2027. With no revenue, $1.5B market cap, and strong cash position (8.29x current ratio), the stock trades on clinical trial readouts and regulatory pathway progress.
Corvus operates as a clinical-stage biotech with no current revenue, burning cash to fund clinical trials. The business model depends on successfully advancing mupadolimab through Phase 2/3 trials, achieving FDA approval, and either commercializing independently or partnering with larger pharma companies. Value creation comes from clinical data demonstrating efficacy in adenosine pathway inhibition for cancer treatment, with potential market opportunity in peripheral T-cell lymphoma (rare disease with limited treatment options) and broader hematologic malignancies. The company's strong balance sheet (8.29x current ratio, minimal debt) provides runway to reach key clinical milestones without near-term dilution risk.
Phase 2/3 clinical trial data readouts for mupadolimab in peripheral T-cell lymphoma (primary endpoint: overall response rate, duration of response)
FDA regulatory pathway updates including breakthrough therapy designation potential or accelerated approval discussions
Partnership announcements or licensing deals with major pharmaceutical companies for commercialization rights
Clinical trial enrollment milestones and expansion into additional cancer indications
Cash runway updates and financing activities (equity offerings, debt facilities) that impact dilution expectations
Binary clinical trial risk: Phase 2/3 trial failure would eliminate primary value driver and likely trigger 60-80% stock decline, as seen historically with failed oncology trials
FDA regulatory pathway uncertainty: Accelerated approval requirements for hematologic malignancies have tightened, with higher bars for single-arm trial designs and surrogate endpoints
Reimbursement pressure: Even with approval, payers increasingly scrutinize oncology drug pricing, particularly for rare indications with limited patient populations
Adenosine pathway competition: Multiple companies developing A2A/A2B receptor antagonists and CD73 inhibitors create mechanism-of-action risk if competitors demonstrate superior efficacy or safety profiles
Standard-of-care evolution: Peripheral T-cell lymphoma treatment landscape evolving with CAR-T therapies and novel targeted agents that could reduce mupadolimab's market opportunity
Big pharma competition: Larger companies with established oncology franchises can out-resource clinical development and commercialization if mechanism validates
Cash burn acceleration: Clinical trial expansion or additional studies could accelerate quarterly burn rate beyond current projections, forcing dilutive financing before key readouts
Equity financing overhang: Pre-revenue biotechs typically require multiple capital raises; future offerings at lower prices would dilute existing shareholders significantly given 20.2x price/book ratio
low - Clinical-stage biotech valuations are driven by binary clinical/regulatory events rather than economic cycles. Cancer treatment demand is non-discretionary and insensitive to GDP fluctuations. However, broader risk appetite affects biotech sector multiples and financing availability.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (potential revenues post-2027). Pre-revenue biotechs are particularly sensitive as they have no near-term earnings to offset higher risk-free rates. Additionally, higher rates can tighten biotech financing markets, making capital raises more dilutive. The company's strong cash position mitigates near-term financing pressure.
Minimal - The company has negligible debt (0.01 debt/equity ratio) and strong liquidity (8.29x current ratio). Credit conditions affect ability to raise non-dilutive debt financing for clinical trials, but equity markets remain primary funding source for clinical-stage biotechs.
growth - Pure clinical-stage speculation attracting biotech-focused hedge funds, venture capital crossover funds, and retail momentum traders. The 266.7% one-year return and 96.3% three-month return indicate high momentum/speculation. Not suitable for value or income investors given no revenue, negative cash flow, and binary risk profile. Institutional ownership likely concentrated among specialized healthcare funds.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions). Negative ROE (-25.8%), negative ROA (-18.7%), and no revenue create pure sentiment-driven trading. Expect 20-50% single-day moves on material clinical updates. Small market cap ($1.5B) amplifies volatility through limited float and liquidity constraints.
